Lu­minopia scores $16M for vir­tu­al re­al­i­ty-based lazy eye treat­ment

A Cam­bridge, MA-based biotech has se­cured an­oth­er $16 mil­lion to ex­pand its dig­i­tal ther­a­peu­tic for lazy eye.

Lu­minopia an­nounced a Se­ries A round on Tues­day from US Ven­ture Part­ners, Broad­fin Ad­vi­sors, Shang­Bay Cap­i­tal and Ver­ti­cal Group. CEO and co-founder Scott Xi­ao was in­spired by a friend who grew up with am­bly­opia, bet­ter known as lazy eye, which typ­i­cal­ly de­vel­ops in ear­ly child­hood.

“It’s ac­tu­al­ly a bit of a mis­nomer in that with pa­tients with am­bly­opia, there’s ac­tu­al­ly no struc­tur­al is­sues with the eye it­self,” Xi­ao said. “It’s ac­tu­al­ly a de­fi­cien­cy in the brain and in the vi­su­al path­ways be­hind one of the eyes.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER